Literature DB >> 22040349

Infection after transrectal ultrasonography-guided prostate biopsy: increased relative risks after recent international travel or antibiotic use.

Uday Patel1, Prokar Dasgupta, Peter Amoroso, Ben Challacombe, James Pilcher, Roger Kirby.   

Abstract

Study Type - Prognosis (case series) Level of Evidence 4 What's known on the subject? and What does the study add? Septicaemia is the most frequent cause of hospitalization after transtrectal prostate biopsy; fatalities have been reported and the incidence is on the rise. This study shows that men with a history of recent international travel or antibiotic use have up to four times increased risk of septicaemia and hospitalization. When they do occur, infections are usually due to multi-resistant E coli and additional care, e.g. delay before biopsy, different antibiotic prophylaxis or transperineal biopsy, should be considered in these cases. OBJECTIVE • To study the infection rate after prostate biopsy in those who have travelled overseas or used antibiotics in the 4 weeks before biopsy. PATIENTS AND METHODS • A total of 316 men with a mean (range) age of 61 (45-85) years were studied. All had undergone transrectal ultrasonography (TRUS)-guided prostate biopsy after standard antibiotic prophylaxis. • Before their biopsy the patients were risk stratified and a history of recent international travel or antibiotic use was recorded. • Those who suffered sufficiently severe infection/sepsis so as to require hospitalization were identified at the end of the study period. • The characteristics of these patients and the types of infections were explored and the relative risk (RR) of infection after recent travel or antibiotic use was calculated. RESULTS • Of the 316 men, 16 were hospitalized with infection. • The group with (n= 16) and without (n= 300) infection were equivalent in age, prostate-specific antigen level, disease status and number of biopsy cores taken. • Either recent travel or antibiotic use were independent risk factors for infection [travel: 8/16 vs 76/300; P= 0.04; RR 2.7 and antibiotic use: 4/16 vs 20/300; P= 0.025; RR 4]. There was no significant pattern in the countries visited or the type of antibiotic used. • Culture results were positive in 10/16 men, and all cultures grew multiresistant Escherichia coli. The strains were uniformly resistant to ciprofloxacin and amoxycillin, and variably resistant to gentamicin and co-amoxiclav, but nearly all were sensitive to meropenem. • All patients made a full recovery after antibiotic and supportive treatment. CONCLUSIONS • Either recent international travel or antibiotic use are independent risk factors for severe infection after TRUS-guided prostate biopsy. • When infection does occur it should be treated aggressively as the causative agent is usually a multiresistant E. coli.
© 2011 THE AUTHORS. BJU INTERNATIONAL © 2011 BJU INTERNATIONAL.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22040349     DOI: 10.1111/j.1464-410X.2011.10561.x

Source DB:  PubMed          Journal:  BJU Int        ISSN: 1464-4096            Impact factor:   5.588


  39 in total

Review 1.  The emerging threat of multidrug-resistant Gram-negative bacteria in urology.

Authors:  Hosam M Zowawi; Patrick N A Harris; Matthew J Roberts; Paul A Tambyah; Mark A Schembri; M Diletta Pezzani; Deborah A Williamson; David L Paterson
Journal:  Nat Rev Urol       Date:  2015-09-01       Impact factor: 14.432

Review 2.  Prevention and treatment of biopsy-related complications.

Authors:  Ramgopal Satyanarayana; Dipen Parekh
Journal:  Curr Urol Rep       Date:  2014-02       Impact factor: 3.092

Review 3.  Transperineal biopsy of the prostate--is this the future?

Authors:  Dwayne T S Chang; Benjamin Challacombe; Nathan Lawrentschuk
Journal:  Nat Rev Urol       Date:  2013-09-24       Impact factor: 14.432

4.  [Infection and sepsis prevention in prostate biopsy].

Authors:  F M E Wagenlehner; A Pilatz; P Waliszewski; T Dansranjavin; W Weidner
Journal:  Urologe A       Date:  2013-10       Impact factor: 0.639

Review 5.  Travel and the Spread of Drug-Resistant Bacteria.

Authors:  Kevin L Schwartz; Shaun K Morris
Journal:  Curr Infect Dis Rep       Date:  2018-06-29       Impact factor: 3.725

6.  Povidone-iodine rectal cleansing and targeted antimicrobial prophylaxis using rectal swab cultures in men undergoing transrectal ultrasound-guided prostate biopsy are associated with reduced incidence of postoperative infectious complications.

Authors:  Ji Won Ryu; Seung Il Jung; Ji Hoon Ahn; Eu Chang Hwang; Ho Song Yu; Taek Won Kang; Dong Deuk Kwon; Kwangsung Park; Jin Woong Kim
Journal:  Int Urol Nephrol       Date:  2016-08-05       Impact factor: 2.370

7.  Radical prostatectomy in the presence of ongoing refractory ESBL Escherichia coli bacterial prostatitis.

Authors:  Louise Catherine McLoughlin; T E D McDermott; John Alan Thornhill
Journal:  BMJ Case Rep       Date:  2014-10-14

8.  Increase of prostate biopsy-related bacteremic complications in southern Finland, 2005-2013: a population-based analysis.

Authors:  K Lahdensuo; A Rannikko; V-J Anttila; A Erickson; A Pätäri-Sampo; M Rautio; H Santti; E Tarkka; M Vaara; K Huotari
Journal:  Prostate Cancer Prostatic Dis       Date:  2016-08-16       Impact factor: 5.554

9.  A single dose of meropenem is superior to ciprofloxacin in preventing infections after transrectal ultrasound-guided prostate biopsies in the era of quinolone resistance.

Authors:  Michael Samarinas; Konstantinos Dimitropoulos; Ioannis Zachos; Stavros Gravas; Anastasios Karatzas; Vasileios Tzortzis
Journal:  World J Urol       Date:  2016-03-07       Impact factor: 4.226

10.  The Human Gut Microbiome as a Transporter of Antibiotic Resistance Genes between Continents.

Authors:  Johan Bengtsson-Palme; Martin Angelin; Mikael Huss; Sanela Kjellqvist; Erik Kristiansson; Helena Palmgren; D G Joakim Larsson; Anders Johansson
Journal:  Antimicrob Agents Chemother       Date:  2015-08-10       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.